Peter G. Tarassoff

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

Howard A. Burris, Malcolm J. Moore, John Sahl Andersen et al. · Journal of Clinical Oncology · 1997 · 5.9K citations

Medicine, Oncology, Pharmacotherapy +16

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.

James L. Abbruzzese, Ralf Grunewald, Elizabeth A. Weeks et al. · Journal of Clinical Oncology · 1991 · 759 citations

Medicine, Oncology, Pharmacology +13

A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer

Mace L. Rothenberg, Malcolm J. Moore, M. Christine Cripps et al. · Annals of Oncology · 1996 · 569 citations · Full text

Medicine, Oncology, Pharmacology +9

Phase II trial of gemcitabine (2,2′-difiuorodeoxycytidine) in patients with adenocarcinoma of the pancreas

Ephraim S. Casper, Mark R. Green, David P. Kelsen et al. · Investigational New Drugs · 1994 · 441 citations

Medicine, Oncology, Pharmacology +11

Saturation of 2?, 2?-difluorodeoxycytidine 5?-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine

Ralf Grunewald, James L. Abbruzzese, Peter G. Tarassoff et al. · Cancer Chemotherapy and Pharmacology · 1991 · 250 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacokinetics +4